Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019. Available in India.

ENHERTU (fam-trastuzumab deruxtecan-nxki) works against unresectable (not removable with surgery) and metastatic HER2-positive breast cancer that has been treated with an anti-HER2 medicine. ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Generic Name: fam-trastuzumab deruxtecan-nxki. Brand Name: ENHERTU.
ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection
is a prescription medicine used for the treatment of patients with treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

Therapeutic indications and Usage ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Name: ENHERTU
Generic Name: Trastuzumab Deruxtecan
Dosage Form & Strength: For injection: 100 mg lyophilized powder in a single-dose vial
Manufactured: Daiichi Sankyo, Inc.
Source Details: Patient Information

Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Healthcare Professional In India If you have any question, please email IPN Support Team or Call Indian Pharma Network for ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

ENHERTU (fam-trastuzumab deruxtecan-nxki)injection
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Facts of ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial..
Source content : www.accessdata.fda.gov

IPN, New Delhi can facilitate patient to import of "ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of ENHERTU (fam-trastuzumab deruxtecan-nxki) injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ENHERTU (fam-trastuzumab deruxtecan-nxki) injection medicine cost price in India.

The order for ENHERTU (fam-trastuzumab deruxtecan-nxki) injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of ENHERTU (fam-trastuzumab deruxtecan-nxki) from authorised distributor.

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer On December 20, 2019, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use
Initial U.S. Approval: 2019.

For injection: 100 mg lyophilized powder in a single-dose vial

For ENHERTU (fam-trastuzumab deruxtecan-nxki)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens For More Details

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised) For More Details

ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer For More Details

Step 1. Send a request for your medicine online:- Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:- We verify your a prescription and necessary documents to import drugs in small quantities for personal use.

Step 3. Permission to Import:- After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:- Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find out -
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in North America – Mexico.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
ENHERTU (fam-trastuzumab deruxtecan-nxki) price in Australia and New Zealand.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Get Access To ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in metastatic HER2-positive breast cancer treatment. Brand Name "ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection" or Generic Name "Fam-trastuzumab deruxtecan-nxki for injection" can be imported for personal use under "patient name basis" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.